Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Mankind Pharma
Deal Size : $1,637.3 million
Deal Type : Acquisition
Mankind Pharma Completes Landmark Acquisition of BSV
Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (carboprost tromethamine), which is indicated for the treatment of post partum haemorrhage.
Product Name : Endoprost
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 23, 2024
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Mankind Pharma
Deal Size : $1,637.3 million
Deal Type : Acquisition
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Mankind Pharma
Deal Size : $1,640.0 million
Deal Type : Acquisition
India's Mankind Pharma to Buy Bharat Serums in a $1.6 Billion Deal
Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (Carboprost Tromethamine), which is indicated for the treatment of post partum haemorrhage.
Product Name : Endoprost
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 26, 2024
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Mankind Pharma
Deal Size : $1,640.0 million
Deal Type : Acquisition
Lead Product(s) : Urinastatin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bharat Serums to assess sepsis drug Ulinastatin for Covid-19
Details : The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2020
Lead Product(s) : Urinastatin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
